ECAU
GILD icon

Everett Capital Advisors (UK)’s Gilead Sciences GILD Stock Holding History

Everett Capital Advisors (UK)’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-179,000
Closed -$12.7M – 36
2017
Q2 		$12.7M Buy
179,000
+136,400
+320% +$9.08M 2.07% 17
2017
Q1 		$2.89M Buy
+42,600
New +$3M 0.5% 26

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Everett Capital Advisors (UK)'s GILD Position: Q3 2017 in Review

Everett Capital Advisors (UK) sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 179,000 shares — an estimated $12.7M sold.

Everett Capital Advisors (UK) first reported a position in GILD in Q1 2017 and held it in 2 quarters. The position peaked at $12.7M in Q2 2017. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • Everett Capital Advisors (UK) reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
  • Everett Capital Advisors (UK) sold 179,000 Gilead Sciences shares in Q3 2017, an estimated $12.7M.
  • Everett Capital Advisors (UK) first reported a position in Gilead Sciences in Q1 2017 and held it in 2 quarters.
  • Everett Capital Advisors (UK)'s Gilead Sciences position peaked at $12.7M in Q2 2017.
  • 1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Everett Capital Advisors (UK)'s 13F filing for Q3 2017, filed 13 Nov 2017.